Article

Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice.

Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
American Journal of Clinical Pathology (Impact Factor: 3.01). 06/2005; 123(5):766-70. DOI: 10.1309/Q0DG-L26R-UCK1-K5EV
Source: PubMed

ABSTRACT Because HER-2 expression in invasive carcinoma of the breast has well-documented ramifications for treatment and prognosis, accurate assessment of HER-2 status is critical. Comparative studies have shown high concordance rates between immunohistochemical analysis and fluorescence in situ hybridization (FISH) in cases with immunohistochemical scores of 0 or 1+ (negative) and 3+ (strongly positive) and low concordance rates among cases with immunohistochemical scores of 2+. The present study was performed to determine concordance rates in a setting more representative of routine clinical practice, in which multiple pathologists submit specimens to a single cytogenetics referral laboratory. We found a higher rate of discordance between immunohistochemical analysis and FISH (approximately 92%) in the groups with immunohistochemical scores of 2+ than reported in other studies. These results strongly support the practice of performing FISH in all cases with immunohistochemical scores of 2+, particularly in routine practice, in which interobserver variability in immunohistochemical scoring among multiple pathologists is likely to be high.

0 Bookmarks
 · 
73 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: The introduction of drugs, whose mechanisms of action are directed against specific molecules involved in cancer initiation and/or progression, has changed the daily workup of breast cancer patients. At present, HER2 expression and/or amplification should be evaluated in every primary invasive breast cancer either at the time of diagnosis or at the time of recurrence, mostly to guide selection of trastuzumab in the adjuvant and/or metastatic setting. The adequate selection of patients is an essential step for indication of anti-HER2 therapy. Objective: This review focuses on the state of the art for HER2 evaluation in breast cancer, as well as expectations regarding future molecular assays based on mechanisms of resistance to HER2-driven therapy. Methods: Data were obtained by searching the PubMed database, including the terms 'HER2', 'in situ hybridisation', 'immunohistochemistry', 'trastuzumab', 'breast cancer', 'therapy', 'resistance' and 'tyrosine-kinase inhibitors', with a preference for updated publications. Conclusion: Pathologists have a central role in the selection of patients who will benefit from anti-HER-based therapies, with a responsibility to obtain the most reliable results for immunohistochemistry and in situ hybridisation techniques. Pre-analytical variables, such as type of fixative and time of fixation, are critical to guarantee consistent and quality assays, as well as to facilitate interpretation and decrease interobserver variability. Rigorous quality control and centralisation of techniques/interpretation of results are recommended to guarantee consistent assays.
    Expert Opinion on Medical Diagnostics 11/2009; 3(6):607-20. DOI:10.1517/17530050903222221
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose:To retrospectively investigate whether the background parenchymal features around a tumor at preoperative dynamic contrast material-enhanced magnetic resonance (MR) imaging are associated with ipsilateral breast tumor recurrence (IBTR)-free survival in patients with ductal carcinoma in situ (DCIS) after breast conservation surgery.Materials and Methods:The institutional review board approved this study, and the requirement for informed consent was waived. Between 2004 and 2009, 215 consecutive women with pure DCIS who had undergone preoperative dynamic contrast-enhanced MR imaging and curative breast conservation surgery were identified. Clinicopathologic features (age, menopausal status, presentation of clinical findings, biopsy method, tumor size, nuclear grade, hormonal receptor status, margin status, and adjuvant therapy) and MR imaging features (lesion size, background parenchymal enhancement grade, fibroglandular density, parenchymal signal enhancement ratio [SER] around the tumor, lesion type, and lesion kinetics) were analyzed. A Cox proportional hazards model was used to determine the association between MR imaging variables and IBTR-free survival after controlling for clinicopathologic variables. Reproducibility of SER measurements was evaluated by using the intraclass correlation coefficient.Results:There were 15 of 215 (7.0%) IBTR cases (nine DCIS cases and six invasive cases) at a median of 36 months (range, 11-61 months). Multivariate analysis showed that higher parenchymal SER (hazard ratio [HR] = 2.028, P < .001 for reader 1; HR = 1.652, P < .001 for reader 2) and larger histologic tumor size (HR = 1.360, P = .009 for reader 1; HR = 1.402, P = .006 for reader 2) were independent factors associated with worse IBTR-free survival. The intraclass correlation coefficient of SER measurements between two readers was 0.852 (95% confidence interval: 0.811, 0.885).Conclusion:Higher parenchymal SER around the tumor at preoperative dynamic contrast-enhanced MR imaging and larger histologic tumor size were independent factors associated with worse IBTR-free survival in patients with DCIS after breast conservation surgery.© RSNA, 2013.
    Radiology 10/2013; 270(3). DOI:10.1148/radiol.13130459 · 6.21 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite strong assertions to the contrary, both in the lay press and in medical publications, the current status of new prognostic or predictive medical tests for human malignancies is a chaotic one with dubious cost-effectiveness. A lack of uniformity exists in how those tests are performed and interpreted, and their meaning is often obscured by poorly constructed and administrated clinical trials. In specific reference to breast carcinoma, these have been enumerated earlier in our discussion, including factors such as recognition of “special” histologic variants, accurate measurement of tumor size, BSR grade, mitotic rate, lymph node substage, and the presence of angiolymphatic invasion. As laboratory methods are refined, and as novel, potentially highly effective biological treatments become available and are tailored to specific neoplasms (e.g., imatinib for gastrointestinal stromal tumors and chronic myelogenous leukemia [1, 2], this situation may well change). At the present time, however, pathologists must be systematic and critical in their assessments of new PPMTs, with a strict threshold for acceptance of those methods as “state-of-the-art” procedures. KeywordsPrediction in anatomic pathology-Breast cancer as model of prognostication-Prognostication in anatomic pathology-Anatomic pathology
    12/2010: pages 61-93;

Full-text (2 Sources)

Download
68 Downloads
Available from
May 26, 2014